A Waltz with Taltz - dermatologists report early adoption of ixekizumab in psoriasis

28 July 2016
2019_biotech_test_vial_discovery_big

At around six weeks after launch of Eli Lilly's (NYSE: LLY) interleukin (IL)-17 inhibitor Taltz (ixekizumab), one-third of surveyed dermatologists (n=99) report trialling the latest biologic, according to RealTime Dynamix: Psoriasis, an independent report issued by Spherix Global Insights on a quarterly basis that provides highly granular brand insights on the psoriasis market.

Although familiarity with Taltz and the ever-present reimbursement and access environment are reported as the leading barriers to adoption, more than 95% of the survey respondents anticipate using Taltz in their practice. Current users expect their use of Taltz to more than triple in the next three months, while during the same time frame more than 20% of non-users expect to initiate trial. [Taltz was launched in the USA in April, but Lilly did not report any sales figures on the drug with its second-quarter results that were released this week: Ed].

Switching from Stelara and Cosentyx

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology